These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26030340)

  • 21. Investigation of anomalous charge variant profile reveals discrete pH-dependent conformations and conformation-dependent charge states within the CDR3 loop of a therapeutic mAb.
    Lan W; Valente JJ; Ilott A; Chennamsetty N; Liu Z; Rizzo JM; Yamniuk AP; Qiu D; Shackman HM; Bolgar MS
    MAbs; 2020; 12(1):1763138. PubMed ID: 32432964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Online Two-Dimensional Approach to Characterizing the Charge-Based Heterogeneity of Recombinant Monoclonal Antibodies Using a 2D-CEX-AEX-MS Workflow.
    Kumar S; Peruri V; Rathore AS
    J Am Soc Mass Spectrom; 2023 Dec; 34(12):2801-2810. PubMed ID: 37994779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elucidation of degradants in acidic peak of cation exchange chromatography in an IgG1 monoclonal antibody formed on long-term storage in a liquid formulation.
    Gandhi S; Ren D; Xiao G; Bondarenko P; Sloey C; Ricci MS; Krishnan S
    Pharm Res; 2012 Jan; 29(1):209-24. PubMed ID: 21845507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative analysis of glycation and its impact on antigen binding.
    Mo J; Jin R; Yan Q; Sokolowska I; Lewis MJ; Hu P
    MAbs; 2018 Apr; 10(3):406-415. PubMed ID: 29436927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of site-specific glycation during process development of a human therapeutic monoclonal antibody.
    Miller AK; Hambly DM; Kerwin BA; Treuheit MJ; Gadgil HS
    J Pharm Sci; 2011 Jul; 100(7):2543-50. PubMed ID: 21287557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring glycation levels of a bispecific monoclonal antibody at subunit level by ultrahigh-resolution MALDI FT-ICR mass spectrometry.
    Gstöttner C; Reusch D; Haberger M; Dragan I; Van Veelen P; Kilgour DPA; Tsybin YO; van der Burgt YEM; Wuhrer M; Nicolardi S
    MAbs; 2020; 12(1):1682403. PubMed ID: 31630606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective Tryptophan Oxidation of Monoclonal Antibodies: Oxidative Stress and Modeling Prediction.
    Pavon JA; Xiao L; Li X; Zhao J; Aldredge D; Dank E; Fridman A; Liu YH
    Anal Chem; 2019 Feb; 91(3):2192-2200. PubMed ID: 30608647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
    Woodall DW; Dillon TM; Kalenian K; Padaki R; Kuhns S; Semin DJ; Bondarenko PV
    MAbs; 2022; 14(1):2004982. PubMed ID: 34978527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific and high-resolution identification of monoclonal antibody fragments detected by capillary electrophoresis-sodium dodecyl sulfate using reversed-phase HPLC with top-down mass spectrometry analysis.
    Wang WH; Cheung-Lau J; Chen Y; Lewis M; Tang QM
    MAbs; 2019 Oct; 11(7):1233-1244. PubMed ID: 31348730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unveiling a glycation hot spot in a recombinant humanized monoclonal antibody.
    Zhang B; Yang Y; Yuk I; Pai R; McKay P; Eigenbrot C; Dennis M; Katta V; Francissen KC
    Anal Chem; 2008 Apr; 80(7):2379-90. PubMed ID: 18307322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain.
    Yan B; Steen S; Hambly D; Valliere-Douglass J; Vanden Bos T; Smallwood S; Yates Z; Arroll T; Han Y; Gadgil H; Latypov RF; Wallace A; Lim A; Kleemann GR; Wang W; Balland A
    J Pharm Sci; 2009 Oct; 98(10):3509-21. PubMed ID: 19475547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of therapeutic proteins by cation exchange chromatography-mass spectrometry and top-down analysis.
    Shi RL; Xiao G; Dillon TM; Ricci MS; Bondarenko PV
    MAbs; 2020; 12(1):1739825. PubMed ID: 32292112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of drug-product-related impurities and variants of a therapeutic monoclonal antibody by higher energy C-trap dissociation mass spectrometry.
    Wang D; Wynne C; Gu F; Becker C; Zhao J; Mueller HM; Li H; Shameem M; Liu YH
    Anal Chem; 2015 Jan; 87(2):914-21. PubMed ID: 25513708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.
    Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD
    MAbs; 2015; 7(1):84-95. PubMed ID: 25524268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches.
    Yang Y; Wang G; Song T; Lebrilla CB; Heck AJR
    MAbs; 2017; 9(4):638-645. PubMed ID: 28281873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening and sequencing of glycated proteins by neutral loss scan LC/MS/MS method.
    Gadgil HS; Bondarenko PV; Treuheit MJ; Ren D
    Anal Chem; 2007 Aug; 79(15):5991-9. PubMed ID: 17571855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Online Collision-Induced Unfolding of Therapeutic Monoclonal Antibody Glyco-Variants through Direct Hyphenation of Cation Exchange Chromatography with Native Ion Mobility-Mass Spectrometry.
    van Schaick G; Domínguez-Vega E; Castel J; Wuhrer M; Hernandez-Alba O; Cianférani S
    Anal Chem; 2023 Feb; 95(8):3932-3939. PubMed ID: 36791123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of variable regions of monoclonal antibodies by top-down mass spectrometry.
    Zhang Z; Shah B
    Anal Chem; 2007 Aug; 79(15):5723-9. PubMed ID: 17591752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
    Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
    BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rates and impact of human antibody glycation in vivo.
    Goetze AM; Liu YD; Arroll T; Chu L; Flynn GC
    Glycobiology; 2012 Feb; 22(2):221-34. PubMed ID: 21930650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.